12th Annual International Congress on the Future of Breast Cancer®
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 19.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial SupportersThis activity is supported by educational grants from Celgene Corporation, Eisai Inc., Genentech, Lilly USA, LLC, and Novartis Pharmaceuticals Corporation.
12th Annual International Congress on the Future of Breast Cancer®
OverviewThe 12th Annual International Congress on the Future of Breast Cancer® is a 3-day educational and scientific meeting that serves as an update on advances in the field with a focus on the clinical implications of breast cancer genetic and phenotypic subtyping. Novel agents and strategies, and improved regimens changing the future of breast cancer therapy, will be highlighted throughout the program. New data and promising studies that provide information about how to optimally individualize breast cancer therapy will be discussed, and controversial issues will be debated. The conference provides a unique opportunity for medical, surgical, and radiation oncologists and other health care professionals to learn from and interact with international leaders in breast cancer in order to increase knowledge, apply new data to practice, and ultimately improve patient outcomes.
Target AudienceThis educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer may also participate.
- Incorporate current guidelines and recent data on local therapies, including advances in surgical and radiation therapy, into the treatment of patients with breast cancer.
- Integrate biomarkers, molecular assays, and other risk assessment tools in treatment decision making for breast cancer when appropriate.
- Review current standards and emerging data regarding systemic therapies for the treatment of early-stage, locally advanced, and metastatic breast cancer.
- Incorporate systemic therapies for breast cancer (including endocrine, cytotoxic, targeted, and bone-modifying agents) into individualized treatment plans for patients based upon an evaluation of efficacy and safety, as well as patient and tumor characteristics.
- Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of breast cancer, and apply clinical trial data appropriately in order to optimize the outcome of individual patients.
- Discuss high-priority translational research and emerging novel agents that are entering clinical trials for patients with breast cancer.
- Select eligible patients with breast cancer for promising clinical trials.
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).
Disclosure Policy and Conflict of Interest Resolution
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multi-step process.
Disclosure ListingThe following individuals have no relevant financial relationships with commercial interests to disclose:
- Jennifer Bellon, MD
- Suzanne Conzen, MD
- David Euhus, MD
- Lori Goldstein, MD
- Alice Ho, MD, MBA
- Minetta C. Liu, MD
- Eleftherious Mamounas, MD, MPH, FACS
- Ellen T. Matloff, MS
- Elizabeth Mittendorf, MD, PhD
- Pamela N. Munster, MD
- Brent Rexer, MD, PhD
- Christy Russell, MD
- Irene L. Wapnir, MD
- Douglas Yee, MD
- Jo Anne Zujewski, MD
The following individuals have relevant financial relationships with commercial interests to disclose:
Kathy Albain, MD – Advisory Board: Genomic Health, Inc; Carey K. Anders, MD – Grant/Research Support: Novartis, Sanofi-Aventis, Geron, BMS; Consultant: Merimack, to-BBB; Matthew Ellis, MB, BChir, PhD – Grant/Research Support: Pfizer, Novartis, Genentech, Astra Zeneca; Stock/Shareholder: Bioclassifier/University Genomic Patients, Pam 50 to Nanostring for the development of Prosigna; Richard Finn, MD – Grant/Research Support: Pfizer, Novartis, Onyx, Bristol-Myers Squibb, Bayer; Suzanne Fuqua, PhD – Grant/Research Support: Janssen; Stefan Gluck, MD PhD FRCPC – Grant/Research Support: Agendia, Genomic Health, Celgene, Eisai, Dara, Genentech; Consultant: Agendia, Genomic Health, Celgene, Eisai, Dara, Genentech; Frankie Ann Holmes, MD – Advisory Board: Eisai; Speaker’s Bureau: Genentech; Ben Jones – Grant/Research Support: Janssen; Stephen Jones, MD - Stock/Shareholder: McKesson Corporation; Carol Lange, PhD – Consultant: Amo Therapeutics, Inc; Ingrid Mayer, MD, MSCI – Grant/Research Support: Novartis; Torsten Nielsen, MD, PhD, FRCPC – Consultant: Bioclassifier, LLC, Nanostring Technologies; Joyce O’Shaughnessy, MD – Consultant: EISAI, Genentech, GlaxoSmith Kline, Janssen BioTech, Lilly, sanofi, Novartis; Speakers Bureau: Genentech, Celgene; Lori Pierce, MD – Grant/Research Support: Blue Cross Blue Shield of Michigan; Consultant: Genomic Health (uncompensated); Hope Rugo, MD – Grant/Research Support: Genentech/Roche, Merck, GSK, Novartis, Plexxikan, Eisai, Nektar, Optimer, Celgene; Speakers Bureau: Genomic Health; Joeseph Sparano, MD - Grant/Research Support: Merck; Consultant: EISAI; Speakers Bureau: BMS; Sandra Swain, MD, FACP - Grant/Research Support: BiPAR Sciences, sanofi Aventis, Genentech/Roche; Consultant: Genentech; Melinda Telli, MD – Grant/ Research Support: Sanofi, Abbott, Novartis; Consultant: Sanofi, Myriad Genetics; Debu Tripathy, MD – Steering Committee on a clinical trial for Genentech/Roche (uncompensated, travel costs covered)
Off-Label DisclosureThis CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
DisclaimerThe opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this CME activity.
Calendar of Events
April 29, 2017
New York, NY
Cancer Summaries and Commentaries™: 2016 Conference Coverage: Advances in the Treatment of Genitourinary Cancers
Apr 29, 2017